Cargando…
Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis – a systematic evaluation of the literature
Summary data on the incidence density (ie, incidence per person-year [PY]) of serious infection, opportunistic infection, and tuberculosis associated with each of the nine biologic therapies currently indicated in rheumatoid arthritis patients are not available. To summarize these data, a systematic...
Autores principales: | Tran, Trung N, Caspard, Herve, Magrini, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074790/ https://www.ncbi.nlm.nih.gov/pubmed/27790021 http://dx.doi.org/10.2147/OARRR.S40526 |
Ejemplares similares
-
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016) -
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016) -
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
por: Riek, Myriam, et al.
Publicado: (2023) -
Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
por: Accortt, Neil A., et al.
Publicado: (2018) -
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
por: Kawashima, Hirotoshi, et al.
Publicado: (2016)